Aminopyrimidines as SYK inhibitors
View Patent ↗The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.
1. A compound having the formula (Ib) or a pharmaceutically acceptable salt thereof:
wherein
R 1 is selected from H, C 1-4 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, and OC 1-4 alkyl;
R 4 is selected from H, C 1-4 alkyl, and C 3-4 cycloalkyl;
Cy is selected from C 4-7 cycloalkyl, oxetanyl, pyrrolidinyl, piperidinyl, and azepanyl;
R y(a) is aminomethyl, OH, OCH 3 , OCH 2 CH 2 OH, F, CN, CO 2 R a(a) , CONR b(a) R c(a) , NR a(a) R a(a) , NHC(O)C 1-3 alkyl (optionally substituted with OH), NHC(O)NH 2 , NHSO 2 NH 2 , NHSO 2 C 1-3 alkyl, or NHSO 2 C 1-3 haloalkyl;
R z(a) is selected from (A) C 1-4 alkyl optionally substituted with one to three groups independently selected from OH, NH 2 , CN, CO 2 R a(a) and CONH 2 , (B) C 1-3 -fluoroalkyl, (C) halogen, (D) CN, (E) COC 1-4 alkyl (optionally substituted with one or two groups independently selected from OR a(a) , CN, CO 2 R a(a) , CONR a(a) R a(a) , and NR a(a) R a(a) ), (F) CO-phenyl (optionally substituted with one or two groups independently selected from ethynyl, CO 2 R a(a) , CN, F and OH), (G) CO—C 3-6 cycloalkyl (optionally substituted with OH or CO 2 R a(a) ), (H) C 0-3 alkyl-CO 2 R a(a) , (I) —C(O)NR b(a) R c(a) , (J) —OR a(a) , (K) —OC(O)R a(a) , (L) —NR b(a) R c(a) , (M) —NHC(O)C 1-4 alkyl (optionally substituted with one to three OH or a CONR a(a) R a(a) ), (N) —NHSO 2 C 1-3 alkyl, (O) —NHSO 2 NH 2 , (P) oxo, (Q) 1,3,4-oxadiazole-2(3H)-one, (R) 1,2,4-oxadiazole-5(4H)-one, (S) SO 2 NH 2 , (T) SO 2 C 1-3 alkyl, (U) SO 2 C 1-3 haloalkyl, and (V) SO 2 Ph;
R a(a) is H or C 1-4 alkyl;
R b(a) and R c(a) are independently selected from (A) H, (B) C 3-6 cycloalkyl optionally substituted with OH, (C) heteroaryl selected from imidazolyl, pyridyl and indolyl, (D) tetrahydrofuranyl, (E) benzyl, (F) phenyl optionally substituted with one or two groups independently selected from (CH 2 ) 0-2 OH and F, (G1) C 1-4 alkyl and (G2) C 1-4 haloalkyl, wherein (G1) and (G2) are each optionally substituted with one to three groups independently selected from (i) OH, (ii) C 3-6 cycloalkyl optionally substituted with one or two groups independently selected from C 1-4 alkyl, CONH 2 , CO 2 H and CH 2 OH, (iii) CONH 2 , (iv) SO 2 NH 2 , (v) SO 2 C 1-4 alkyl, (vi) 4- to 7-membered monocyclic heterocyclyl optionally substituted with one or two groups independently selected from oxo, (CH 2 ) 0-2 OH, and C 1-4 alkyl, (vii) a 5- or 6-membered heteroaryl optionally substituted with one or two groups independently selected from carboxy, (CH 2 ) 0-2 OH, and C 1-4 alkyl, (viii) CN, (x) OC 1-4 alkyl, (ix) CO 2 H, (xii) NR a(a) C(O)C 1-4 alkyl, (x) phenyl optionally substituted with one or two groups independently selected from (CH 2 ) 0-2 OH, SO 2 NH 2 , CF 3 , F and Cl, (xi) 1-pyrrolidinyl optionally substituted with oxo, (xii) 1-imidazolidinyl optionally substituted with oxo, (xiii) 1-piperidinyl optionally substituted with oxo, and (xiv) 4-morpholinyl; or
R b(a) and R c(a) together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycle having 0 to 1 additional heteroatom selected from N, O and S, wherein said heterocycle is optionally substituted with one or two groups independently selected from oxo, CN, (CH 2 ) 0-2 OH, acetyl, benzyl, SO 2 C 1-4 alkyl, CONH 2 , methoxymethyl, carboxymethyl, CO 2 R a(a) and C 1-4 alkyl;
p is 0 to 4; and
q is 0, 1 or 2.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein Cy is cyclohexyl.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein Cy is cyclohexyl, q is 1, p is 0, 1 or 2, and R z(a) is selected from CO 2 R a(a) , CONR b(a) R c(a) and NHC(O)C 1-4 alkyl optionally substituted with OH.
4. The compound of claim 3 or a pharmaceutically acceptable salt thereof wherein R y(a) is OH.
5. The compound of claim 3 or a pharmaceutically acceptable salt thereof wherein R y(a) is CONH 2 .
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein Cy is azepanyl, p is 0, q is 1, and R z(a) is oxo.
7. The compound of claim 6 or a pharmaceutically acceptable salt thereof wherein R y(a) is OH.
8. A compound having the formula (Ic) or a pharmaceutically acceptable salt thereof:
wherein
Z is —CR z(b) R z(c) —, —N(R z(d) )—, —CH 2 —N(R z(d) )—, or —NHC(O)—;
p′ is 0 to 3, with the proviso that p′ is 0 when Z is —NHC(O)—;
R z(b) is selected from (A) H, (B) C 1-4 alkyl optionally substituted with one to three groups independently selected from OH, NH 2 , CN, CO 2 R a(a) and CONH 2 , (C) halogen, (D) CN, (E) —C(O)R a(a) , (F) —C(O) 2 R a(a) , (G) —C(O)NR b(a) R c(a) , (H) —OR a(a) , (I) —OC(O)R a(a) , (J) —NR b(a) R c(a) , (K) —NHC(O)C 1-4 alkyl (optionally substituted with OH), (L) —NHSO 2 C 1-3 alkyl, (M) —NHSO 2 NH 2 , (N) 1,3,4-oxadiazole-2(3H)-one, and (O) 1,2,4-oxadiazole-5(4H)-one;
R z(c) is H or methyl;
R z(d) is selected from (A) H, (B) C 1-3 alkyl optionally substituted with a group selected from CO 2 R a(a) and CONH 2 , (C) C 1-3 fluoroalkyl, (D) COC 1-4 alkyl (optionally substituted with one or two groups independently selected from OR a(a) , CN, CO 2 R a(a) , CONR a(a) R a(a) , and NR a(a) R a(a) ), (E) CO-phenyl (optionally substituted with one or two groups independently selected from ethynyl, CO 2 R a(a) , CN, F and OH), (F) CO—C 3-6 cycloalkyl (optionally substituted with OH or CO 2 R a(a) ), (G) C 0-3 alkyl-CO 2 R a(a) , (H) CONR a(a) R a(a) , (I) CONH-phenyl (optionally substituted with one or two groups independently selected from C 1-4 alkyl, CN, and Cl), (J) CONH—C 3-6 cycloalkyl, (K) SO 2 NH 2 , (L) SO 2 C 1-3 alkyl, (M) SO 2 C 1-3 haloalkyl, and (N) SO 2 Ph;
R 1 is selected from H, C 1-4 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, and OC 1-4 alkyl;
R 4 is selected from H, C 1-4 alkyl, and C 3-4 cycloalkyl;
R y(a) is aminomethyl, OH, OCH 3 , OCH 2 CH 2 OH, F, CN, CO 2 R a(a) , CONR b(a) R c(a) , NR a(a) R a(a) , NHC(O)C 1-3 alkyl (optionally substituted with OH), NHC(O)NH 2 , NHSO 2 NH 2 , NHSO 2 C 1-3 alkyl, or NHSO 2 C 1-3 haloalkyl;
R a(a) is H or C 1-4 alkyl; and
R b(a) and R c(a) are independently selected from (A) H, (B) C 3-6 cycloalkyl optionally substituted with OH, (C) heteroaryl selected from imidazolyl, pyridyl and indolyl, (D) tetrahydrofuranyl, (E) benzyl, (F) phenyl optionally substituted with one or two groups independently selected from (CH 2 ) 0-2 OH and F, (G1) C 1-4 alkyl and (G2) C 1-4 haloalkyl, wherein (G1) and (G2) are each optionally substituted with one to three groups independently selected from (i) OH, (ii) C 3-6 cycloalkyl optionally substituted with one or two groups independently selected from C 1-4 alkyl, CONH 2 , CO 2 H and CH 2 OH, (iii) CONH 2 , (iv) SO 2 NH 2 , (v) SO 2 C 1-4 alkyl, (vi) 4- to 7-membered monocyclic heterocyclyl optionally substituted with one or two groups independently selected from oxo, (CH 2 ) 0-2 OH, and C 1-4 alkyl, (vii) a 5- or 6-membered heteroaryl optionally substituted with one or two groups independently selected from carboxy, (CH 2 ) 0-2 OH, and C 1-4 alkyl, (viii) CN, (x) OC 1-4 alkyl, (ix) CO 2 H, (xii) NR a(a) C(O)C 1-4 alkyl, (x) phenyl optionally substituted with one or two groups independently selected from (CH 2 ) 0-2 OH, SO 2 NH 2 , CF 3 , F and Cl, (xi) 1-pyrrolidinyl optionally substituted with oxo, (xii) 1-imidazolidinyl optionally substituted with oxo, (xiii) 1-piperidinyl optionally substituted with oxo, and (xiv) 4-morpholinyl; or
R b(a) and R c(a) together with the nitrogen atom to which they are attached form a 6- or 7-membered heterocycle having 0 to 1 additional heteroatom selected from N, O and S, wherein said heterocycle is optionally substituted with one or two groups independently selected from oxo, CN, (CH 2 ) 0-2 OH, acetyl, benzyl, SO 2 C 1-4 alkyl, CONH 2 , methoxymethyl, carboxymethyl, CO 2 R a(a) and C 1-4 alkyl.
9. The compound of claim 8 or a pharmaceutically acceptable salt thereof wherein Z is —CHR z(b) —, and p′ is 0, 1 or 2.
10. The compound of claim 8 or a pharmaceutically acceptable salt thereof wherein Z is —NHC(O)—.
11. The compound of claim 9 or a pharmaceutically acceptable salt thereof wherein R z(b) is —C(O) 2 R a(a) , —C(O)NHR b(a) or —C(O)NH 2 .
12. The compound of claim 8 or a pharmaceutically acceptable salt thereof wherein R z(b) is —C(O) 2 R a(a) , —C(O)NHR b(a) or —C(O)NH 2 , and R y(a) is OH or CONH 2 .
13. The compound of claim 1 having the formula (Id) or a pharmaceutically acceptable salt thereof:
wherein
p′ is 0, 1 or 2;
R y(a) is selected from OH, OCH 3 , F, CN and CONH 2 ;
R z(b) is selected from (a) C 1-4 alkyl optionally substituted with one or more groups independently selected from OH, NH 2 , CN, CO 2 R a(a) and CONH 2 , (b) CN, (c) —C(O) 2 R a(a) , (d) —C(O)NHR b(a) , (e) —NHC(O)C 1-4 alkyl (optionally substituted with OH), (f) 1,3,4-oxadiazole-2(3H)-one, and (g) 1,2,4-oxadiazole-5(4H)-one;
R 1 is selected from H, methyl, isopropyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, cyclopropyl and isopropyloxy;
R 4 is selected from H, methyl and cyclopropyl;
R a(a) is H or C 1-4 alkyl; and
R b(a) is H, C 1-4 alkyl optionally substituted 2-oxo-1-pyrrolidinyl.
14. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein R y(a) is OH.
15. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein R z(b) is CO 2 H, CONH 2 , CONH(CH 2 ) 3 -(2-oxo-1-pyrrolidinyl), or NHC(O)CH 2 OH.
16. The compound of claim 1 selected from the group consisting of:
(1R,4S)-4-[5-(3-cyclopropyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid;
(1S,4R)-4-[5-(3-cyclopropyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid;
(1S,4R)-4-[5-(3-{[4-(difluoromethyl)pyrimidin-2-yl]amino}-5-methylphenyl)-1,3-thiazol-2-yl]-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid;
trans-4-hydroxy-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
cis-4-hydroxy-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
5-hydroxy-5-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]azepan-2-one;
cis-4-[(hydroxyacetyl)amino]-1-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxamide; and
(1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]cyclohexanecarboxamide;
(1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
(1R,4S)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
(1S,4S)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
(1R,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
(1R,4S)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxamide;
(1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxamide;
(1S,4R)4-{5-[3-({4-[(1R)-1-fluoroethyl]pyrimidin-2-yl}amino)-5-methylphenyl]-1,3-thiazol-2-yl}-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid; and
(1S,4R)4-{5-[3-({4-[(1S)-1-fluoroethyl]pyrimidin-2-yl}amino)-5-methylphenyl]-1,3-thiazol-2-yl}-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid;
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 selected from the group consisting of:
trans-4-hydroxy-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
cis-4-hydroxy-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
5-hydroxy-5-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]azepan-2-one;
cis-4-[(hydroxyacetyl)amino]-1-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxamide;
4-hydroxy-2,5-dimethyl-4-(5-{3-methyl-5-[(4-methylpyrimidin-2-yl)amino)]phenyl]-1,3-thiazol-2-yl}cyclohexanecarboxylic acid;
4-hydroxy-2,5-dimethyl-4-[5-{3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl}-1,3-thiazol-2-yl]cyclohexanecarboxylic acid; or
a pharmaceutically acceptable salt thereof.
18. A compound which is 5-hydroxy-5-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]azepan-2-one, or a pharmaceutically acceptable salt thereof.
19. A compound which is (1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]cyclohexanecarboxamide, or a pharmaceutically acceptable salt thereof.
20. A compound which is cis-4-[(hydroxyacetyl)amino]-1-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxamide, or a pharmaceutically acceptable salt thereof.
21. A compound which is (1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
22. A compound which is (1S,4R)-4-{5-[3-({4-[(1S)-1-fluoroethyl]pyrimidin-2-yl}amino)-5-methylphenyl]-1,3-thiazol-2-yl}-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
23. A compound which is (1S,4R)-4-{5-[3-({4-[(1R)-1-fluoroethyl]pyrimidin-2-yl}amino)-5-methylphenyl]-1,3-thiazol-2-yl}-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
24. A compound which is 4-hydroxy-2,5-dimethyl-4-(5-{3-methyl-5-[(4-methylpyrimidin-2-yl)amino)]phenyl]-1,3-thiazol-2-yl}cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
25. A compound which is 4-hydroxy-2,5-dimethyl-4-[5-{3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl}-1,3-thiazol-2-yl]cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
26. A compound, which is 5-hydroxy-5-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]azepan-2-one.
27. A compound, which is (1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]cyclohexanecarboxamide.
28. A compound, which is cis-4-[(hydroxyacetyl)amino]-1-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxamide.
29. A compound, which is (1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid.
30. A compound, which is (1S,4R)-4-{5-[3-({4-[(1S)-1-fluoroethyl]pyrimidin-2-yl}amino)-5-methylphenyl]-1,3-thiazol-2-yl}-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid.
31. A compound, which is (1S,4R)-4-{5-[3-({4-[(1R)-1-fluoroethyl]pyrimidin-2-yl}amino)-5-methylphenyl]-1,3-thiazol-2-yl}-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid.
32. The pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
33. A method for the treatment of rheumatoid arthritis which comprises administering to a mammal in need thereof a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
34. A method for the treatment of asthma which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
35. The method of claim 33 , wherein the compound administered is 5-hydroxy-5-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]azepan-2-one, or a pharmaceutically acceptable salt thereof.
36. The method of claim 33 , wherein the compound administered is (1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]cyclohexanecarboxamide, or a pharmaceutically acceptable salt thereof.
37. The method of claim 33 , wherein the compound administered is (1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
38. The method of claim 33 , wherein the compound b administered is (1S,4R)-4-{5-[3-({4-[(1S)-1-fluoroethyl]pyrimidin-2-yl}amino)-5-methylphenyl]-1,3-thiazol-2-yl}-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
39. The method of claim 33 , wherein the compound administered is (1S,4R)-4-{5-[3-({4-[(1R)-1-fluoroethyl]pyrimidin-2-yl}amino)-5-methylphenyl]-1,3-thiazol-2-yl}-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
40. A method for the treatment of systemic lupus erythematosis which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.